Abstract Library

#3067 Somatostatin Analogs in Real‐World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran)

Introduction: The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ameziane N, Behourah Z, Aida M, Ahed Messaoud M, Bousahba A,

Keywords: GEP-NET, Somatostatin analogs, anti proliferative action, anti secretory action, Management real world practice,

#2987 68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors

Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Peiró I, Vercher-Conejero J, Suils-Ramón J, Hernández L, Teulé A,

Keywords: 68Ga-DOTATOC PET/CT, metastatic neuroendocrine tumors,

#2686 Survivorship Care Model for Patients with Metastatic Neuroendocrine Tumors

Introduction: Neuroendocrine tumors(NET)are rare often indolent tumors. Approximately 22% of patients (pt's) present with metastatic disease at diagnosis and can live with metastatic disease for years. These pt's often don't identify as cancer survivors and don't meet the criteria for care in traditional survivorship clinics

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Laffan A

Authors: Laffan A,

Keywords: neuroendocrine, survivorship, multidisciplinary, metastatic,

#2247 Efficacy of Oral Chemotherapy with Capecitabine and Temozolomide (Captem) in Patients with Metastatic Neuroendocrine Tumors (NETS). A Single-Institution Experience

Introduction: CapTem chemotherapy regimen is a standard treatment for NETs but limited scientific data on its efficacy and tolerability are available

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Smiroldo V, Carnaghi C, Lania A, Bonifacio C, Pepe G,

Keywords: CapTem, metastatic neuroendocrine tumors,

#2232 Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience

Introduction: Interval reduction of somatostatin analogs (SSAs) is a possibly strategy for elderly patients with progressive metastatic neuroendocrine tumors (NETs). Patients with diagnosis of NET are >75 years old in the 25% of cases. No randomized studies are available to evaluate efficacy of this treatment schedule.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Puliafito I, Prestifilippo A, Colarossi C, Giuffrida P, Castorina L,

Keywords: somatostatin, analogs, interval, reduction, experience, elderly,